IE
JANX icon

Israel Englander’s Janux Therapeutics JANX Stock Holding History

Israel Englander’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,700
Closed -$448K – 6292
2024
Q2 		$448K Buy
+10,700
New +$502K ﹤0.01% 4657

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Israel Englander's JANX Position: Q2 2026 in Review

Israel Englander increased its Janux Therapeutics (JANX) stake by 30% in Q2 2026, buying an estimated $1.71M and bringing the position to 504,544 shares worth $7.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2569.

Israel Englander first reported a position in JANX in Q2 2021 and has held it in 14 quarters since. 196 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Israel Englander held 504,544 shares of Janux Therapeutics worth $7.75M as of Q2 2026.
  • Israel Englander bought 117,734 Janux Therapeutics shares in Q2 2026, an estimated $1.71M.
  • Janux Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2569 holding.
  • Israel Englander first reported a position in Janux Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • 196 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.